{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:01:11Z","timestamp":1794916871067,"version":"4.9.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"National Key Research Project-Accurate Medical Research","award":["2016YFC0905701"],"award-info":[{"award-number":["2016YFC0905701"]}]},{"name":"Foundation for Young Scholars of Guangzhou Medical University"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.rmed.2020.105983","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T12:25:03Z","timestamp":1589631903000},"page":"105983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD"],"prefix":"10.1016","volume":"172","author":[{"given":"Meng-meng","family":"Mao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-peng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-ping","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-xuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-min","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong-chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmed.2020.105983_bib1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrrheum.2018.41","article-title":"Classification of myositis","volume":"14","author":"Lundberg","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib2","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmed.2020.105983_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/nan.12380","article-title":"Integrated classification of inflammatory myopathies","volume":"43","author":"Allenbach","year":"2017","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.rmed.2020.105983_bib4","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.autrev.2017.05.003","article-title":"Integrated diagnosis Project for inflammatory myopathies: an association between autoantibodies and muscle pathology","volume":"16","author":"Suzuki","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.rmed.2020.105983_bib5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1002\/art.21023","article-title":"Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis","volume":"52","author":"Sato","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmed.2020.105983_bib6","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/art.24621","article-title":"RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease","volume":"60","author":"Sato","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.rmed.2020.105983_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaad.2017.12.010","article-title":"Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: a concise review with an emphasis on distinctive clinical features","volume":"78","author":"Kurtzman","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.rmed.2020.105983_bib8","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","article-title":"Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients","volume":"57","author":"Sato","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmed.2020.105983_bib9","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12890-018-0622-8","article-title":"MDA-5 associated rapidly progressive interstitial lung disease with recurrent Pneumothoraces: a case report","volume":"18","author":"Alqatari","year":"2018","journal-title":"BMC Pulm. Med."},{"key":"10.1016\/j.rmed.2020.105983_bib11","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","article-title":"A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment","volume":"27","author":"Koichi","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib12","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jbspin.2013.07.016","article-title":"Salvage B-cell depletion therapy in rapidly progressive dermatomyositis-associated interstitial lung disease","volume":"81","author":"N\u00e9el","year":"2014","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.rmed.2020.105983_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/5386797","article-title":"Effective administration of rituximab in anti-MDA5 antibody\u2013positive dermatomyositis with rapidly progressive interstitial lung disease and refractory cutaneous involvement: a case report and literature review","volume":"12","author":"Ogawa","year":"2017","journal-title":"Case Reports in Rheumatology"},{"key":"10.1016\/j.rmed.2020.105983_bib14","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib15","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.2169\/internalmedicine.56.7956","article-title":"Dermatomyositis with rapidly progressive interstitial lung disease treated with rituximab: a report of 3 cases in Japan","volume":"56","author":"Tokunaga","year":"2017","journal-title":"Intern. Med."},{"key":"10.1016\/j.rmed.2020.105983_bib16","first-page":"1","article-title":"Successful multi-target therapy using corticosteroid, tacrolimus, cyclophosphamide, and rituximab for rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis","volume":"26","author":"Watanabe","year":"2015","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib17","first-page":"306","article-title":"Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody","volume":"61","author":"Bruzzese","year":"2009","journal-title":"Reumatismo"},{"key":"10.1016\/j.rmed.2020.105983_bib18","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1186\/s13063-017-2134-x","article-title":"Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial","volume":"18","author":"den Broeder","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.rmed.2020.105983_bib19","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/039463201102400135","article-title":"Therapeutic effectiveness of minimal doses of rituximab in a patient with rhumatoid arthritis","volume":"24","author":"Bruzzese","year":"2011","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.rmed.2020.105983_bib20","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"European League against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmed.2020.105983_bib21","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.chest.2016.04.007","article-title":"Management of myositis-related interstitial lung disease","volume":"150","author":"Morisset","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2020.105983_bib22","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrrheum.2018.42","article-title":"Treatment in myositis","volume":"14","author":"Oddis","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib23","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2217\/imt.13.49","article-title":"The future of B cell-targeted therapies in Sj\u00f6gren's syndrome","volume":"5","author":"Cornec","year":"2013","journal-title":"Immunotherapy"},{"key":"10.1016\/j.rmed.2020.105983_bib24","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.rmed.2020.105983_bib25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib26","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","article-title":"Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease","volume":"121","author":"Hozumi","year":"2016","journal-title":"Respir. Med."},{"key":"10.1016\/j.rmed.2020.105983_bib27","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/rheumatology\/key420","article-title":"Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease","volume":"58","author":"Takanashi","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmed.2020.105983_bib28","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12931-020-1296-3","article-title":"Progression of fibrosing interstitial lung disease","volume":"21","author":"Wong","year":"2020","journal-title":"Respir. Res."},{"key":"10.1016\/j.rmed.2020.105983_bib29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11926-013-0359-6","article-title":"Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis","volume":"15","author":"Kiely","year":"2013","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.rmed.2020.105983_bib30","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: a review of the published literature","volume":"28","author":"Wallace","year":"2016","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib31","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.rmed.2020.105983_bib32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.rmed.2020.105983_bib33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib34","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s10067-015-2935-9","article-title":"Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis\/dermatomyositis","volume":"34","author":"Chen","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.rmed.2020.105983_bib35","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/rheumatology\/keq149","article-title":"Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis","volume":"49","author":"Gono","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmed.2020.105983_bib36","first-page":"5","article-title":"IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis\/dermatomyositis","volume":"36","author":"Kawasumi","year":"2014","journal-title":"BioMed Res. Int."},{"key":"10.1016\/j.rmed.2020.105983_bib37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12016-017-8608-5","article-title":"Could lymphocyte profiling be useful to diagnose systemic autoimmune diseases?","volume":"53","author":"Carvajal Alegria","year":"2017","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.rmed.2020.105983_bib38","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1346-8138.1993.tb03825.x","article-title":"Analysis of lymphocyte subpopulations in peripheral blood in adult and juvenile cases of dermatomyositis","volume":"20","author":"Ishida","year":"1993","journal-title":"J. Dermatol."},{"key":"10.1016\/j.rmed.2020.105983_bib39","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1007\/s00296-011-2323-y","article-title":"Anti-MDA5 antibody is associated with A\/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis","volume":"32","author":"Chen","year":"2012","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.rmed.2020.105983_bib40","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody\u2013associated antisynthetase syndrome: anti-ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J. Rheumatol."},{"issue":"Suppl 2","key":"10.1016\/j.rmed.2020.105983_bib41","article-title":"B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis","volume":"44","author":"Looney","year":"2005","journal-title":"Rheumatology"},{"key":"10.1016\/j.rmed.2020.105983_bib42","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.seminhematol.2010.01.007","article-title":"CD20-Targeted therapy: the next generation of antibodies","volume":"47","author":"van Meerten","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.rmed.2020.105983_bib43","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611120301232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611120301232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:10:21Z","timestamp":1760616621000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611120301232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":43,"alternative-id":["S0954611120301232"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2020.105983","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ultra-low dose rituximab as add-on therapy in anti-MDA5-positive patients with polymyositis \/dermatomyositis associated ILD","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2020.105983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105983"}}